Alamar Biosciences adds Robert Ragusa to board
Rhea-AI Filing Summary
Alamar Biosciences, Inc. (ALMR) reported that its board of directors appointed Robert Ragusa to the board effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the company’s 2027 Annual Meeting of Stockholders.
Ragusa was also appointed to the board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. He will receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into its standard indemnification agreement. The company states there were no arrangements leading to his selection and no related person transactions requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Appointment date: August 28, 2026
Effective date: September 1, 2026
Term expiry: 2027 Annual Meeting of Stockholders
3 metrics
Appointment date
August 28, 2026
Date the board appointed Robert Ragusa as director
Effective date
September 1, 2026
Date Robert Ragusa’s board appointment becomes effective
Term expiry
2027 Annual Meeting of Stockholders
End of initial term as Class I Director
Key Terms
Emerging growth company, Non-Employee Director Compensation Policy, indemnification agreement, related person transactions
4 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Non-Employee Director Compensation Policy financial
"under the terms of the Company’s Non-Employee Director Compensation Policy"
indemnification agreement regulatory
"Mr. Ragusa will enter into the Company’s standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
FAQ
What board change did Alamar Biosciences (ALMR) announce on August 28, 2026?
Alamar Biosciences announced that Robert Ragusa was appointed to its board of directors on August 28, 2026, with the appointment effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the 2027 Annual Meeting of Stockholders.
What committees will Robert Ragusa serve on at Alamar Biosciences (ALMR)?
Robert Ragusa was appointed to Alamar Biosciences’ Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, giving him roles across the company’s key oversight and governance committees as part of his board service.
How will Robert Ragusa be compensated as a director of Alamar Biosciences (ALMR)?
Robert Ragusa will be compensated under Alamar Biosciences’ Non-Employee Director Compensation Policy, which is described in the company’s final prospectus filed with the SEC on April 17, 2026. The filing does not restate the specific compensation amounts or structure.
When does Robert Ragusa’s initial term on the Alamar Biosciences (ALMR) board end?
Robert Ragusa will serve as a Class I Director with an initial term expiring at Alamar Biosciences’ 2027 Annual Meeting of Stockholders. His future service beyond that would depend on renomination and stockholder approval at that meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
